In its second dossier, the drug manufacturer deviated from the appropriate comparator therapy and again provided no relevant data for the assessment of the added benefit of perampanel, experts report.
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/1...
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/1...